Aivita Biomedical adds Matthew Katz to its Board along with raising $12.5m Series B-2 financing

– USA, CA –  AIVITA Biomedical, Inc., a biotechnology company specializing in innovative stem cell applications, today announced the first closing of its $25 million Series B-2 preferred stock investment round led by Matthew Katz, an entrepreneur and investor who has been appointed to AIVITA’s board of directors. The financing round also includes other healthcare-focused venture capital firms.

“We are excited to welcome Matthew to our board of directors,” said Dr. Hans S. Keirstead, Chairman and CEO of AIVITA. “Matt brings deep experience in corporate development, operations and partnership strategy to AIVITA at a time when our programs are expanding and maturing.”

About Matthew Katz

Matthew Katz is the founder and CEO of Verifi, Inc., a customized software solution that systematically identifies payment risk. He is also the head of Zoo Station, his family office focused on investing in early-stage startups. He has successfully founded and partnered several businesses and consulting firms and is a welcome addition to AIVITA’s board of directors.

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems that support its therapeutic pipeline and commercial line of skincare products. All proceeds from the sale of AIVITA’s skincare products support the treatment of people with cancer.

For more information: http://aivitabiomedical.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.